IN2014DN01605A - - Google Patents

Info

Publication number
IN2014DN01605A
IN2014DN01605A IN1605DEN2014A IN2014DN01605A IN 2014DN01605 A IN2014DN01605 A IN 2014DN01605A IN 1605DEN2014 A IN1605DEN2014 A IN 1605DEN2014A IN 2014DN01605 A IN2014DN01605 A IN 2014DN01605A
Authority
IN
India
Prior art keywords
gene
ret
fusion
cases
mutation
Prior art date
Application number
Other languages
English (en)
Inventor
Takashi Kohno
Koji TSUTA
Original Assignee
Nat Cancer Ct
Lsip Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nat Cancer Ct, Lsip Llc filed Critical Nat Cancer Ct
Publication of IN2014DN01605A publication Critical patent/IN2014DN01605A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57423—Specifically defined cancers of lung
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
IN1605DEN2014 2011-08-04 2012-08-03 IN2014DN01605A (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2011171256 2011-08-04
PCT/JP2012/069799 WO2013018882A1 (ja) 2011-08-04 2012-08-03 Ｋｉｆ５ｂ遺伝子とｒｅｔ遺伝子との融合遺伝子、並びに該融合遺伝子を標的としたがん治療の有効性を判定する方法

Publications (1)

Publication Number Publication Date
IN2014DN01605A true IN2014DN01605A (da) 2015-05-15

Family

ID=47629396

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1605DEN2014 IN2014DN01605A (da) 2011-08-04 2012-08-03

Country Status (8)

Country Link
US (1) US9216172B2 (da)
EP (1) EP2740742B1 (da)
JP (1) JP6032616B2 (da)
KR (1) KR20140047138A (da)
CN (1) CN103764676A (da)
CA (1) CA2848369A1 (da)
IN (1) IN2014DN01605A (da)
WO (1) WO2013018882A1 (da)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3205654T (lt) 2010-05-20 2019-05-27 Array Biopharma, Inc. Makrocikliniai junginiai kaip trk kinazės slopikliai
JP5780527B2 (ja) 2010-09-02 2015-09-16 学校法人 久留米大学 単分子ｄｎａから形成される環状ｄｎａの作成方法
WO2013028817A1 (en) 2011-08-23 2013-02-28 Foundation Medicine , Inc. Novel kif5b-ret fusion molecules and uses thereof
US9416358B2 (en) 2011-08-31 2016-08-16 Kurume University Method for exclusive selection of circularized DNA from monomolecular DNA in circularizing DNA molecules
US10023855B2 (en) 2011-10-31 2018-07-17 Macrogen, Inc. Fusion protein comprising C-terminal domain of RET protein and use thereof as a diagnosing marker
JP5759568B2 (ja) 2012-09-25 2015-08-05 中外製薬株式会社 Ｒｅｔ阻害剤
CA3009552A1 (en) * 2013-03-15 2014-09-18 Expression Pathology, Inc. Srm assay to indicate cancer therapy
WO2015025866A1 (ja) 2013-08-20 2015-02-26 独立行政法人国立がん研究センター 肺がんで見出された新規融合遺伝子
WO2016127074A1 (en) 2015-02-06 2016-08-11 Blueprint Medicines Corporation 2-(pyridin-3-yl)-pyrimidine derivatives as ret inhibitors
CA2992586A1 (en) 2015-07-16 2017-01-19 Array Biopharma, Inc. Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
CN105255927B (zh) * 2015-09-30 2018-07-27 温州医科大学附属第一医院 一种kiaa1217-ret融合基因
EP4331585A3 (en) 2015-11-02 2024-05-15 Blueprint Medicines Corporation Inhibitors of ret
US10183928B2 (en) 2016-03-17 2019-01-22 Blueprint Medicines Corporation Inhibitors of RET
WO2018017983A1 (en) 2016-07-22 2018-01-25 Blueprint Medicines Corporation Compounds useful for treating disorders related to ret
JOP20190077A1 (ar) 2016-10-10 2019-04-09 Array Biopharma Inc مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret
TWI704148B (zh) 2016-10-10 2020-09-11 美商亞雷生物製藥股份有限公司 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
CN110191705A (zh) * 2016-12-01 2019-08-30 亚尼塔公司 治疗癌症的方法
WO2018136661A1 (en) 2017-01-18 2018-07-26 Andrews Steven W SUBSTITUTED PYRAZOLO[1,5-a]PYRAZINE COMPOUNDS AS RET KINASE INHIBITORS
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
JP2020519672A (ja) 2017-05-15 2020-07-02 ブループリント メディシンズ コーポレイション ＲＥＴ阻害剤とｍＴＯＲＣ１阻害剤との組合せ及び異常なＲＥＴ活性によって媒介されるがんを処置するためのその使用
SG11202001212SA (en) * 2017-08-21 2020-03-30 Taiho Pharmaceutical Co Ltd Fusion protein of dctn1 protein with ret protein
WO2019143991A1 (en) 2018-01-18 2019-07-25 Array Biopharma Inc. SUBSTITUTED PYRAZOLO[3,4-d]PYRIMIDINE COMPOUNDS AS RET KINASE INHIBITORS
TWI802635B (zh) 2018-01-18 2023-05-21 美商亞雷生物製藥股份有限公司 作為ｒｅｔ激酶抑制劑之經取代吡咯并[2,3-d]嘧啶化合物
CA3087972C (en) 2018-01-18 2023-01-10 Array Biopharma Inc. Substituted pyrazolyl[4,3-c]pyridinecompounds as ret kinase inhibitors
LT3773589T (lt) 2018-04-03 2024-02-12 Blueprint Medicines Corporation Ret inhibitorius, skirtas naudoti vėžiui gydyti, esant ret pakitimui
WO2020033838A2 (en) 2018-08-10 2020-02-13 Blueprint Medicines Corporation Treatment of egfr-mutant cancer
CA3111984A1 (en) 2018-09-10 2020-03-19 Array Biopharma Inc. Fused heterocyclic compounds as ret kinase inhibitors
CN111154872A (zh) * 2019-12-31 2020-05-15 浙江大学 用于检测肺癌驱动性基因突变的探针及试剂盒
CN111909987A (zh) * 2020-07-31 2020-11-10 浙江科途医学科技有限公司 用于kif5b-ret融合基因检测的试剂组合物、试剂盒及检测系统
CN113637709B (zh) * 2021-08-14 2023-01-17 中国农业科学院兰州兽医研究所 Kif5b基因作为靶点在抑制口蹄疫病毒复制中的应用
JP2023177142A (ja) * 2022-06-01 2023-12-13 国立研究開発法人国立がん研究センター Ｒｅｔキナーゼ阻害剤によるがん治療の有効性を判定する方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7598052B2 (en) * 2005-10-11 2009-10-06 The Regents Of The University Of Michigan Expression profile of thyroid cancer
JPWO2007049624A1 (ja) 2005-10-24 2009-04-30 武田薬品工業株式会社 癌の予防・治療剤
JP2010509289A (ja) * 2006-11-09 2010-03-25 アボット ゲーエムベーハー ウント コンパニー カーゲー チロシンキナーゼ阻害剤の経口投与用薬学的剤形
EP1920767A1 (en) 2006-11-09 2008-05-14 Abbott GmbH & Co. KG Melt-processed imatinib dosage form
WO2010000012A1 (en) * 2008-07-03 2010-01-07 The University Of Sydney Method for preventing transport of a neurotropic virus
EP2599878A4 (en) * 2010-07-26 2014-02-12 Astellas Pharma Inc NEW METHOD FOR DETECTING FUSED BODIES RET
JP2014005206A (ja) 2010-10-22 2014-01-16 Astellas Pharma Inc アリールアミノヘテロ環カルボキサミド化合物

Also Published As

Publication number Publication date
EP2740742A4 (en) 2015-06-17
CN103764676A (zh) 2014-04-30
JPWO2013018882A1 (ja) 2015-03-05
EP2740742B1 (en) 2018-03-14
CA2848369A1 (en) 2013-02-07
EP2740742A1 (en) 2014-06-11
US20140221404A1 (en) 2014-08-07
US9216172B2 (en) 2015-12-22
JP6032616B2 (ja) 2016-11-30
WO2013018882A1 (ja) 2013-02-07
KR20140047138A (ko) 2014-04-21

Similar Documents

Publication Publication Date Title
IN2014DN01605A (da)
PH12018500317A1 (en) Salts of an lsd1 inhibitor
MX2012003770A (es) Metodos para la modulacion de autofagia a traves de la modulacion de productos de genes que aumentan la autofagia.
MX2016016115A (es) Metodo para tratar cancer usando una combinacion de inhibidores de chk1 y relacionado con atm y rad3 (atr).
MX2022015737A (es) Compuestos para mejorar el empalme del acido ribonucleico mensajero (arnm).
GB201103062D0 (en) Method
MX368513B (es) Métodos in vitro para el pronóstico, diagnóstico y diseño de una terapia de metástasis de cáncer de pulmón.
MX2013005392A (es) Compuestos de hidroxiamida pirimidina como inhibidores de la proteina deacetilasa y metodo de uso de estos.
SG10201906673WA (en) Artificial nucleic acid molecules
MA40240A (fr) Composés hétéroaryle d'inhibition de la kinase
EP4116293A3 (en) Rho kinase inhibitors
JOP20120246B1 (ar) مركبات و تركيبات كمثبطات كيناز c-Kit
NZ601606A (en) Identification, assessment, and therapy of cancers with innate or acquired resistance to alk inhibitors
MX2018004170A (es) Biomarcadores relacionados con enfermedades mediadas por interleucina-33 (il-33) y usos de los mismos.
EA201400117A1 (ru) Способы и нуклеиновые кислоты для определения прогноза у больных раком
MX2013015158A (es) Compuestos inhibidores de metaloenzima.
MX2014002486A (es) Compuestos y composiciones como inhibidores de cinasa pdgfr.
IN2014DN06164A (da)
MD3362066T2 (ro) Terapie combinată pentru tratamentul tumorilor maligne
CA2864161A1 (en) Inhibition of the glycine cleavage system for treatment of cancer
MX2015004610A (es) Metodo para diagnostico, pronostico y tratamiento de metastasis de cancer de prostata usando c-maf.
BR112014024487A2 (pt) métodos para aumentar a eficácia da terapia baseada em cd37
MX371119B (es) Productos de combinacion con los inhibidores de cinasa de tirosina y su uso.
WO2015048793A3 (en) Nucleic acid biomarker and use thereof
MX2014014097A (es) Biomarcadores para determinar la respuesta eficaz de tratamientos en pacientes de carcinoma hepatocelular (chc).